JP2023159112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023159112A5 JP2023159112A5 JP2023123893A JP2023123893A JP2023159112A5 JP 2023159112 A5 JP2023159112 A5 JP 2023159112A5 JP 2023123893 A JP2023123893 A JP 2023123893A JP 2023123893 A JP2023123893 A JP 2023123893A JP 2023159112 A5 JP2023159112 A5 JP 2023159112A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 119
- 229920001184 polypeptide Polymers 0.000 claims 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims 55
- 150000001413 amino acids Chemical class 0.000 claims 48
- 108091008874 T cell receptors Proteins 0.000 claims 17
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024178808A JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565383P | 2017-09-29 | 2017-09-29 | |
| US62/565,383 | 2017-09-29 | ||
| JP2020517556A JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
| PCT/US2018/051285 WO2019067243A1 (en) | 2017-09-29 | 2018-09-17 | T CELL RECEPTORS RECOGNIZING P53 MUTE |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Division JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178808A Division JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023159112A JP2023159112A (ja) | 2023-10-31 |
| JP2023159112A5 true JP2023159112A5 (enExample) | 2023-11-29 |
| JP7573075B2 JP7573075B2 (ja) | 2024-10-24 |
Family
ID=63714167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Active JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
| JP2023123893A Active JP7573075B2 (ja) | 2017-09-29 | 2023-07-28 | 変異型ｐ５３を認識するｔ細胞受容体 |
| JP2024178808A Active JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Active JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178808A Active JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11939365B2 (enExample) |
| EP (2) | EP3688027B1 (enExample) |
| JP (3) | JP7324193B2 (enExample) |
| KR (2) | KR102762272B1 (enExample) |
| CN (2) | CN111386282B (enExample) |
| AU (2) | AU2018342246B2 (enExample) |
| BR (1) | BR112020006012A2 (enExample) |
| CA (1) | CA3077024A1 (enExample) |
| CR (4) | CR20240302A (enExample) |
| DK (1) | DK3688027T3 (enExample) |
| EA (1) | EA202090757A1 (enExample) |
| ES (1) | ES3056082T3 (enExample) |
| FI (1) | FI3688027T3 (enExample) |
| IL (1) | IL273515B1 (enExample) |
| MA (1) | MA50651A (enExample) |
| MX (4) | MX421596B (enExample) |
| PT (1) | PT3688027T (enExample) |
| SG (1) | SG11202002636PA (enExample) |
| WO (1) | WO2019067243A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3551221T (pt) | 2016-12-08 | 2022-01-18 | Immatics Biotechnologies Gmbh | Novos recetores de células t e imunoterapia empregando os mesmos |
| KR102809909B1 (ko) * | 2017-09-29 | 2025-05-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
| KR20220013569A (ko) * | 2019-05-27 | 2022-02-04 | 프로빈셜 헬스 서비시즈 오쏘리티 | Kras 항원을 표적화하는 면역요법용 구조체 |
| US12479902B2 (en) * | 2019-06-27 | 2025-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing R175H or Y220C mutation in P53 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| US20230321240A1 (en) * | 2020-09-04 | 2023-10-12 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | T cell receptors recognizing r273c or y220c mutations in p53 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| AU2022268998A1 (en) * | 2021-05-07 | 2023-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| CN118541388A (zh) * | 2021-10-29 | 2024-08-23 | 侯亚非 | 识别p53中r175h突变的t细胞受体及其应用 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| US20240035027A1 (en) * | 2022-05-04 | 2024-02-01 | University Of Massachusetts | Oligonucleotides for pms2 modulation |
| CN116063577B (zh) * | 2022-11-18 | 2025-02-07 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| AU2024298426A1 (en) * | 2023-07-25 | 2026-01-15 | Memorial Hospital For Cancer And Allied Diseases | T cell receptors targeting tp53 hotspot mutations and uses thereof |
| WO2025060149A1 (zh) * | 2023-09-22 | 2025-03-27 | 上海市第一人民医院 | 一种分离的tcr及其用途 |
| WO2025226769A1 (en) * | 2024-04-24 | 2025-10-30 | Bluesphere Bio, Inc. | T cell receptors targeting minor histocompatibility antigen lrh-1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770749B2 (en) | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
| DK1546188T3 (da) * | 2001-06-05 | 2008-10-27 | Altor Bioscience Corp | P53-bindende T-cellereceptormolekyler og anvendelser deraf |
| EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| WO2015019318A1 (en) * | 2013-08-07 | 2015-02-12 | Yeda Research And Development Co. Ltd. | Peptides capable of reactivating p53 mutants |
| CN106414748B (zh) * | 2014-02-14 | 2021-05-28 | 得克萨斯州大学系统董事会 | 嵌合抗原受体及制备方法 |
| CN106459924A (zh) * | 2014-04-23 | 2017-02-22 | 得克萨斯州大学系统董事会 | 用于疗法中的嵌合抗原受体(car)及其制备方法 |
| KR102618267B1 (ko) | 2014-05-29 | 2023-12-27 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항-인유두종바이러스 16 e7 t 세포 수용체 |
| JP6686008B2 (ja) * | 2014-10-02 | 2020-04-22 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| CA2963364A1 (en) | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| CA2978628A1 (en) | 2015-03-03 | 2016-09-09 | Caris Mpi, Inc. | Molecular profiling for cancer |
| AU2016258845B2 (en) * | 2015-05-01 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
-
2018
- 2018-09-17 CR CR20240302A patent/CR20240302A/es unknown
- 2018-09-17 ES ES18780006T patent/ES3056082T3/es active Active
- 2018-09-17 MX MX2020003504A patent/MX421596B/es unknown
- 2018-09-17 PT PT187800065T patent/PT3688027T/pt unknown
- 2018-09-17 AU AU2018342246A patent/AU2018342246B2/en active Active
- 2018-09-17 WO PCT/US2018/051285 patent/WO2019067243A1/en not_active Ceased
- 2018-09-17 EP EP18780006.5A patent/EP3688027B1/en active Active
- 2018-09-17 JP JP2020517556A patent/JP7324193B2/ja active Active
- 2018-09-17 CR CR20240303A patent/CR20240303A/es unknown
- 2018-09-17 EP EP25200391.8A patent/EP4647442A3/en active Pending
- 2018-09-17 CN CN201880074539.8A patent/CN111386282B/zh active Active
- 2018-09-17 DK DK18780006.5T patent/DK3688027T3/da active
- 2018-09-17 KR KR1020207012344A patent/KR102762272B1/ko active Active
- 2018-09-17 KR KR1020257002917A patent/KR20250024096A/ko active Pending
- 2018-09-17 CN CN202411117183.5A patent/CN118955684A/zh active Pending
- 2018-09-17 EA EA202090757A patent/EA202090757A1/ru unknown
- 2018-09-17 US US16/651,242 patent/US11939365B2/en active Active
- 2018-09-17 SG SG11202002636PA patent/SG11202002636PA/en unknown
- 2018-09-17 BR BR112020006012-7A patent/BR112020006012A2/pt unknown
- 2018-09-17 FI FIEP18780006.5T patent/FI3688027T3/fi active
- 2018-09-17 CR CR20200170A patent/CR20200170A/es unknown
- 2018-09-17 MA MA050651A patent/MA50651A/fr unknown
- 2018-09-17 CA CA3077024A patent/CA3077024A1/en active Pending
- 2018-09-17 CR CR20250153A patent/CR20250153A/es unknown
-
2020
- 2020-03-23 IL IL273515A patent/IL273515B1/en unknown
- 2020-07-13 MX MX2024005676A patent/MX2024005676A/es unknown
- 2020-07-13 MX MX2024005677A patent/MX2024005677A/es unknown
- 2020-07-13 MX MX2024005678A patent/MX2024005678A/es unknown
-
2023
- 2023-07-28 JP JP2023123893A patent/JP7573075B2/ja active Active
-
2024
- 2024-02-21 US US18/583,139 patent/US20240270814A1/en active Pending
- 2024-10-11 JP JP2024178808A patent/JP7814467B2/ja active Active
- 2024-10-28 AU AU2024227695A patent/AU2024227695A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023159112A5 (enExample) | ||
| JP2017536825A5 (enExample) | ||
| JP2018535647A5 (enExample) | ||
| Ho et al. | Bacteriophage λ protein c II binds promoters on the opposite face of the DNA helix from RNA polymerase | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2020511936A5 (enExample) | ||
| JP2021500010A5 (enExample) | ||
| CN112225806B (zh) | 一种人源抗新型冠状病毒（SARS-CoV-2）的中和活性单克隆抗体 | |
| JP2014500002A5 (enExample) | ||
| JP2020534828A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP6907229B2 (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| JP2007506417A5 (enExample) | ||
| JP2015506945A5 (enExample) | ||
| CN103562218A (zh) | 显性负性hsp110突变体及其在预测和治疗癌症中的用途 | |
| CN115335400A (zh) | 结合整合素avb8的抗体及其用途 | |
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| Iizuka et al. | APOBEC 3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression | |
| CN118652334A (zh) | 一种靶向钙粘蛋白17的纳米抗体及其应用 | |
| EP3770167A1 (en) | Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus | |
| CN113667011B (zh) | 制备抗原结合单元的方法 | |
| KR20240008997A (ko) | 사스-코로나 바이러스 2 중화 항체 | |
| JPWO2020264269A5 (enExample) | ||
| AU2018405442A1 (en) | Binding molecule having neutralizing activity against middle east respiratory syndrome-coronavirus | |
| JP2009523004A5 (enExample) |